New Danish Obesity Drug Amycretin Wins EU Approval This Month

The European Medicines Agency is expected to announce approval of Novo Nordisk’s next-generation obesity drug, amycretin, on either May 18 or May 19. The drug has shown strong results in late-stage trials. This news is likely to generate enormous search interest both in Denmark and globally, given the high demand for weight-loss treatments. Novo Nordisk confirmed on May 15 that the European Medicines Agency adopted a positive opinion for its new obesity treatment, amycretin. This recommendation paves the way for official approval across the EU. The European Commission is expected to publish the formal approval decision within 48 hours of the announcement. Amycretin is a once-daily pill that combines a GLP-1 analog with an amylin analog. In phase 3 clinical trials, patients who took the drug lost an average of 15% of their body weight over a 68-week period. Analysts see the drug as a potential blockbuster, with peak annual sales forecast to exceed $10 billion. The approval marks a major milestone for Novo Nordisk, which already dominates the obesity market with its previous drug, Wegovy. Danish business circles and Copenhagen stock exchange watchers are closely tracking the news. The development reinforces Denmark’s strong position in global pharmaceutical trade.